Healthier brains may be more resilient to early Alzheimer’s disease
Peer-Reviewed Publication
In honor of Alzheimer's Awareness Month, we’re exploring the science and stories surrounding Alzheimer’s disease.
Updates every hour. Last Updated: 22-Jun-2026 16:16 ET (22-Jun-2026 20:16 GMT/UTC)
People who carry the APOE2 version of the apolipoprotein E gene are more likely to live to advanced age and are partly protected against Alzheimer's disease, but scientists have struggled to explain why. A new study from the Buck Institute for Research on Aging, now published in Aging Cell, offers a mechanistic answer: APOE2 helps human neurons keep their DNA intact and resist becoming senescent, a damaged, dysfunctional state that accumulates with age and contributes to neurodegeneration.
A new study led by researchers at Trinity College Dublin in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, estimates the value-based prices of these medicines across 174 countries. The study shows that while disease-modifying therapies (DMTs) may offer substantially greater health benefits than usual care, their real-world impact will depend on whether they are priced in ways that health systems can afford.
Having a biological age older than chronological age is associated with a greater likelihood of developing dementia, a new study has shown. By combining measures of biological ageing and genetic risk, researchers have identified individuals at a higher risk of developing dementia and those who will develop the disease at a younger age.